Journal article

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.

Edward J Gane, Mitchell L Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine AM Stedman, Mitchell N Davis, Federico Hinestrosa, Hadas Dvory-Sobol, KC Huang, Anu Osinusi, John McNally, Diana M Brainard, John G McHutchison, Alex J Thompson, Mark S Sulkowski, undefined GS-US-342-1553 Investigators

Hepatology | Published : 2017

Abstract

The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstr..

View full abstract